Suppr超能文献

c-erbB-2蛋白在正常和肿瘤性尿路上皮中的表达:对人类膀胱癌无不良预后影响

Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer.

作者信息

Lee S E, Chow N H, Chi Y C, Tzai T S, Yang W H, Lin S N

机构信息

Department of Pathology, Medical College, National Cheng Kung University, Taiwan, ROC.

出版信息

Anticancer Res. 1994 May-Jun;14(3B):1317-24.

PMID:7915094
Abstract

The clinical significance of c-erb B-2 expression in urinary bladder cancer remains controversial. We performed an immunohistochemical study to examine the expression of c-erb B-2 in non-neoplastic urothelium (n = 12) and transitional cell carcinoma of the urinary bladder (n = 82). c-erb B-2 protein was localized in superficial and some intermediate cells of non-neoplastic urothelium. A total of 29 out of 82 (35%) tumors were positive for c-erb B-2 over-expression. There was no significant association of c-erbB-2 expression with tumor grade (p = 0.12), stage (p = 0.93), DNA ploidy status (p = 0.56) and the sex of patients (p = 0.5). Expression of epidermal growth factor receptor and Ki-67 index was available in 33 cases. Both parameters showed no apparent association with c-erbB-2 expression (p = 0.53 and 0.58 respectively). Factors correlated with poor patient survival by univariate analysis were tumor stage (p = 0.0001), tumor grade (p = 0.001), development of second recurrence (p = 0.002) and negative expression of c-erbB-2 (p = 0.017). Important indicators associated with first recurrence were tumor stage (p = 0.028), and c-erbB-2 expression with the risk of second recurrence (p = 0.031). Multivariate survival analysis revealed that tumor stage was among the most important prognostic factors (p = 0.029), followed by tumors without c-erbB-2 expression (p = 0.031) with a median follow-up at 46 months. The age of patients and c-erbB-2 expression were significantly associated with developing second recurrence (p = 0.031 and 0.046 respectively). The results indicate that expression of c-erbB-2 is independent of the stage and grade of bladder cancer. Although c-erbB-2 status can discriminate subpopulations with a high risk of recurrence, evaluation of its expression in paraffin-embedded tumors does not indicate poor prognosis for patients with urinary bladder cancer. To address this discrepancy a better understanding of the regulatory mechanism and physiological properties of c-erbB-2 protein in urothelium is required.

摘要

c-erb B-2在膀胱癌中的临床意义仍存在争议。我们进行了一项免疫组织化学研究,以检测c-erb B-2在非肿瘤性尿路上皮(n = 12)和膀胱移行细胞癌(n = 82)中的表达。c-erb B-2蛋白定位于非肿瘤性尿路上皮的表层和一些中间层细胞。82例肿瘤中有29例(35%)c-erb B-2过表达呈阳性。c-erbB-2表达与肿瘤分级(p = 0.12)、分期(p = 0.93)、DNA倍体状态(p = 0.56)及患者性别(p = 0.5)均无显著相关性。33例患者有表皮生长因子受体表达及Ki-67指数数据。这两个参数与c-erbB-2表达均无明显相关性(分别为p = 0.53和0.58)。单因素分析显示,与患者生存不良相关的因素有肿瘤分期(p = 0.0001)、肿瘤分级(p = 0.001)、二次复发(p = 0.002)及c-erbB-2阴性表达(p = 0.017)。与首次复发相关的重要指标是肿瘤分期(p = 0.028)以及c-erbB-2表达与二次复发风险(p = 0.031)。多因素生存分析显示,肿瘤分期是最重要的预后因素之一(p = 0.029),其次是无c-erbB-2表达的肿瘤(p = 0.031),中位随访时间为46个月。患者年龄和c-erbB-2表达与二次复发显著相关(分别为p = 0.031和0.046)。结果表明,c-erbB-2的表达独立于膀胱癌的分期和分级。虽然c-erbB-2状态可区分复发风险高的亚群,但评估其在石蜡包埋肿瘤中的表达并不能表明膀胱癌患者预后不良。为解决这一差异,需要更好地了解c-erbB-2蛋白在上皮中的调控机制和生理特性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验